Data as Reported: 2025-08
| Month | Contract ID | Vendor | Total Cost | Effective Expiry Date |
Unit(s) | Description |
|---|---|---|---|---|---|---|
| 2025-08 |
sID: 5500003226
|
QIAGEN NORTH AM | $8,000,000.00 | 2022-07-01 2029-09-24 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2025-06 |
sID: 5500003226
|
QIAGEN NORTH AM | $8,000,000.00 | 2022-07-01 2029-09-24 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2025-05 |
sID: 5500003226
|
QIAGEN NORTH AM | $8,000,000.00 | 2022-07-01 2029-09-24 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2025-03 |
sID: 5500003226
|
QIAGEN NORTH A | $3,000,000.00 | 2022-07-1 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2025-02 |
sID: 5500003226
|
QIAGEN NORTH AM | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2025-01 |
sID: 5500003226
|
QIAGEN NORTH AM | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-10 |
sID: 5500003226
|
QIAGEN NORTH AM | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-05 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-04 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-03 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-02 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2024-01 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-12 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-11 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-10 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-09 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-08 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-07 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-06 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-05 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-04 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-03 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-02 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2023-01 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2022-11 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2022-10 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2022-09 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2022-08 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| 2022-07 |
sID: 5500003226
|
QIAGEN NORTH AMERICAN HOLDINGS INC | $3,000,000.00 | 2022-07-01 2027-06-30 |
|
Clinical Laboratory Reagents and Tests (Blood Grouping, Diag |
| CA SoS Checked | 1632354887 |
| CA SoS Registration Name | QIAGEN NORTH AMERICAN HOLDINGS INC. |
| CA SoS Registration | C2220444 |
| CA SoS Agent | CORPORATION SERVICE COMPANY WHICH WILL DO BUSINESS IN CALIFORNIA AS CSC - LAWYERS INCORPORATING SERVICE (C1592199) |
| CA SoS Registration Jurisdiction | CALIFORNIA |
| CA SoS Registration Date | 02/25/2000 |